Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US

Journal of Medical Economics

Volumn 18, Issue 6, 2015, Pages 447-456

  Cohen, Russell ^a   Skup, Martha ^b   Ozbay, A Burak ^b   Rizzo, Joanne ^b   Yang, Min ^c   Diener, Melissa ^c   Chao, Jingdong ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b ABBVIE INC   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

Absenteeism; Colitis; Cost of illness; Economics; Health expenditures; Healthcare costs; Ulcerative

Indexed keywords

PRESCRIPTION DRUG;

ADULT; ARTICLE; COMORBIDITY; COST BENEFIT ANALYSIS; DESCRIPTIVE RESEARCH; EMERGENCY WARD; EMPLOYEE; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ULCERATIVE COLITIS; UNITED STATES; ADOLESCENT; COST OF ILLNESS; ECONOMICS; EMERGENCY HEALTH SERVICE; EMPLOYMENT; EPIDEMIOLOGY; INSURANCE; MEDICAL LEAVE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; COLITIS, ULCERATIVE; COMORBIDITY; COST OF ILLNESS; EMERGENCY SERVICE, HOSPITAL; EMPLOYMENT; FEMALE; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; MALE; MIDDLE AGED; PRESCRIPTION DRUGS; SICK LEAVE; UNITED STATES; YOUNG ADULT;

EID: 84935885151     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1021353     Document Type: Article

References (45)

1. Inflammatory bowel disease (IBD). Atlanta, GA: Centers for Disease Control and Prevention, 2011. http://www.cdc.gov/ibd/. Accessed December 2, 2013
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: Up or down? World J Gastroenterol 2006;12:6102-8
3. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 2013;58:519-25
4. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334:841-8
5. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 1988;94:1075-9
6. Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981;2:270-1
7. Campieri M, De Franchis R, Bianchi Porro G, et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 1990;25:663-8
8. Friedman LS, Richter JM, Kirkham SE, et al. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: A randomized, controlled trial. Am J Gastroenterol 1986;81:412-18
9. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis. Aliment Pharmacol Ther 1995;9:293-300
10. Kam L, Cohen H, Dooley C, et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996;91:1338-42
11. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9
12. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005;Issue 1. Art. No.:CD004277
13. Bossa F, Latiano A, Rossi L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: A randomized, controlled study. Am J Gastroenterol 2008;103:2509-16
14. Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: A randomized, double-blind trial. Am J Gastroenterol 2007;102:601-8
15. Bar-Meir S, Fidder HH, Faszczyk M, et al. Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. Dis Colon Rectum 2003;46:929-36
16. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX- extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE I study. Gastroenterology 2012;143:1218-26
17. Travis SPL, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: Results from the randomised CORE II study. Gut 2014;63:433-41
18. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004;99:1122-8
19. Sakuraba A, Sato T, Morohoshi Y, et al. Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: A pilot study. Ther Apher Dial 2012;16:213-18
20. Yamamoto S, Nakase H, Matsuura M, et al. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol 2011;45:526-30
21. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353: 2462-76
22. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65
23. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology 2014;146:85-95
24. Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: The ECCO-EpiCom cohort. Inflamm Bowel Dis 2014;20:36-46
25. Frolkis AD1, Dykeman J, Negro? n ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: A systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145: 996-1006.
26. Hueting WE, Gooszen HG, Van Laarhoven CJ. Sexual function and continence after ileo pouch anal anastomosis: A comparison between a meta-analysis and a questionnaire survey. Int J Colorectal Dis 2004;19:215-18
27. Hueting WE, Buskens E, Van det Tweel I, et al. Results and complications after ileal pouch anal anastomosis: A meta-analysis of 43 observational studies comprising 9317 patients. Dig Surg 2005;22:69-79
28. Cohen RD, Yu AP, Wu EQ, et al. Systematic review: The costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31: 693-707
29. ICD-9-CM Official Guidelines for Coding and Reporting. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/icd/icd9cm-addenda- guidelines.htm#guidelines. Accessed January 12, 2015
30. National Drug Code Directory. US Department of Health and Human Services. http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm. Accessed January 12, 2015
31. Rogler G. Medical management of ulcerative colitis. Dig Dis 2009;27:542-9
32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83
33. Romano PS, Roos LL, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1993;46:1075-9
34. The Consumer Price Index. CPI Detailed Report, January 2014. Washington, DC: United States Department of Labor/United States Bureau of Labor Statistics. http://www.bls.gov/cpi/. Accessed March 4, 2014
35. Boonen A, Dagnelie PC, Feleus A, et al. The impact of inflammatory bowel disease on labor force participation: Results of a population sampled casecontrol study. Inflamm Bowel Dis 2002;8:382-9
36. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008;50: 1261-72
37. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in United States children and adults. Gastroenterology 2008;135:1907-13.
38. Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm 2008;14:352-62.
39. Hillson E, Dybicz S, Waters HC, et al. Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. J Occup Environ Med 2008;50:969-77
40. Hawkins K, Wang S, Rupnow MFT. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007;49:368-74
41. Goetzel RZ, Hawkins K, Ozminkowski RJ, et al. The health and productivity cost burden of the ''top 10'' physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med 2003;45:5-14
42. Signorovitch JE, Macaulay D, Diener M, et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab 2013;15:335-41
43. Macaulay D, Ivanova J, Birnbaum H, et al. Direct and indirect costs associated with Dupuytren's contracture. J Med Econ 2012;15:664-71
44. Kirson NY, Birnbaum HG, Ivanova JI, et al. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population. Appl Health Econ Health Policy 2011;9:377-87
45. Johnson S, Davis M, Kaltenboeck A, et al. Early retirement and income loss in patients with early and advanced Parkinson's disease. Appl Health Econ Health Policy 2011;9:367-76